Embryonic stem (ES) cells have provided a valid model to understand early events of mammalian lineage specification and differentiation, leading to important insights into the mechanisms that control embryogenesis at the molecular and cellular levels. Furthermore, ES cells have recently evoked great scientific interest as ideal candidates for the generation of tissues for transplantation therapies. In this respect, particular attention has been paid to the molecules and signaling pathways triggering ES cell differentiation. The EGF-CFC Cripto protein is a key regulator of ES cells fate. The cripto gene is expressed both in ES cells and during the early phases of embryo development, while, in the adult, it is reactivated in a wide range of epithelial cancers. This review will discuss recent findings on the molecular basis of Cripto signaling in ES cell differentiation, providing an intriguing link between stem cell and tumor biology.
Introduction
During normal embryonic development, cells divide rapidly and migrate to their appropriate positions along the body axis to form tissues and organs. These primitive cells undergo morphological and physiological changes by regulating the expression of various repertoires of genes in a process known as cell differentiation. At the same time, during cancer progression, tumor cells revert to an embryonic-like state, where cells divide rapidly and migrate inappropriately through the body. Findings emerging from different research fields are reinforcing the idea that the same molecules and mechanisms operate during embryonic development and in the adult, under both physiological and pathological conditions. It is thus convincing that by studying the interface between normal embryo development and tumor biology, one may gain a better understanding of the molecular and genetic events responsible for cancer, thereby revealing new strategies for developing more effective cancer therapies. However, the molecular mechanisms controlling early events of mammalian development are still largely unknown due to the complexity of the in vivo situation. In order to overcome this limitation, in vitro culture systems present a great advantage. In this respect, both embryonal carcinoma (EC) cells and embryonal stem (ES) cells represent powerful tools to study early events of mammalian development. ES cells are pluripotent cells derived from the inner cell mass (ICM) of a blastocyst (Evans and Kaufman, 1981; Martin, 1981) . The value of ES cells is derived from their capacity to contribute to all three germ layers ectoderm, mesoderm and endoderm; although they cannot give rise to extraembryonic tissues (throphoblast and placenta). A defining feature of ES cells is the ability to undergo prolonged symmetrical cell division in culture (self-renewal) to produce identical pluripotent progeny. So far, there is no direct evidence that ES cells and cells from the ICM are equivalent (Chambers and Smith, 2004) ; indeed, the ICM exists only transiently and does not operate as a stem cell compartment in vivo. It is thus suggested that these cells may arise through selection and adaptation to the culture environment (Smith, 2001; Chambers and Smith, 2004) .
Mouse ES cells have been instrumental in the emergence of knockout strategies as a powerful tool to understand mammalian gene function. In addition, in vitro differentiation of ES cells has been useful to study the very early steps of mammalian lineage specification and differentiation (Loebel et al., 2003) . Indeed, differentiation of both mouse and human ES cells follows the hierarchical set of signals that regulate embryonic development in the generation of the germ layers and cell types (Thomson et al., 1998; Schuldiner et al., 2000; Munoz-Sanjuan and Brivanlou, 2002) ; thus, ES cells might provide a valid model to understand the complex network of signaling interactions in the embryo. Furthermore, ES cells have recently evoked great scientific interest given their expected capacity to self-renew and differentiate efficiently into the desired cell type, thus representing new sources for cell replacement therapy.
In this scenario, understanding the early events of lineage specification, commitment and differentiation is crucial both for the prospects of controlling stem cells differentiation for biomedical application and for the functional dissection of signaling pathways activated in the early stages of embryogenesis and eventually reactivated in tumorigenesis.
Based on the above considerations, the onco-developmental factor Cripto, involved both in physiological events associated with development and pathological events linked to tumorigenesis, turned out to have a key role (Adamson et al., 2002) .
Cripto and the EGF-CFC family
Cripto is the original member of a family of vertebrate signaling molecules, the EGF-CFC family which includes: human, mouse and chick Cripto (Ciccodicola et al., 1989; Dono et al., 1993; Colas and Schoenwolf, 2000) ; human and mouse Cryptic (Shen et al., 1997) , Xenopus FRL-1 (Kinoshita et al., 1995) and Zebrafish one-eyed pinhead (Zhang et al., 1998) . All EGF-CFC proteins contain a signal sequence for extracellular secretion, a characteristic EGF-like domain, a second cysteine-rich region called the CFC domain, and a hydrophobic C-terminus (Shen and Schier, 2000) . Initially described as secreted molecules, members of this family are extracellular membrane proteins, anchored to the lipid bilayer through a glycosilphosphatidylinositol (GPI) moiety (Minchiotti et al., 2000) .
Early studies of cripto were focused on its possible role in cell transformation and tumor progression (Salomon et al., 1999; Persico et al., 2001) . Cripto expression was first found in human and mouse EC cells and male teratocarcinomas and was demonstrated to be over-expressed in breast, cervical, ovarian, gastric, lung, colon and pancreatic carcinomas, in contrast to normal tissues where cripto expression was invariably absent (for a review see Salomon et al., 1999) . Cripto can apparently function as an oncogene by inducing cell transformation, migration, invasion and epithelial-tomesenchimal transition (EMT) in mammary epithelial cells and in breast and cervical carcinomas cells (Ebert et al., 2000; Wechselberger et al., 2001; Strizzi et al., 2004) . EMT is one of the key processes in morphogenesis and tumor progression; it involves a dramatic change in cells phenotype by which a well-differentiated and polarized epithelial cell is converted into a mesenchymal cell with a leading edge that facilitates its migration through the extracellular matrix, and thus the colonization of different structures. The acquisition of this phenotype is fundamental for the formation of many tissues and organs during embryonic development and constitutes the first step in the metastatic process in tumors of epithelial origin (Thiery, 2003) .
Recently, a great effort has been undertaken to unravel the role of cripto in development and ES cell differentiation (Ding et al., 1998; Xu et al., 1998) . In mouse embryos, cripto is expressed early in the ICM and the throphoblast cells of the blastocyst (Johnson et al., 1994) . At 6.5 dpc cripto is expressed in the epiblast and at the primitive streak stage in the forming mesoderm. Later on, cripto expression is associated with the developing heart structures. In 8.5 dpc embryos cripto is expressed in the myocardium of the developing heart tube and in the outflow region, conotroncus, of the heart at 9.5-10 days of gestation, when the heart develops into a functional chambered organ. After 10.5 dpc no expression is detected (Dono et al., 1993) . This expression pattern suggests that cripto may play a role in the early events leading to heart morphogenesis. Mouse embryos deficient for the cripto gene die around day 7.5 of embryogenesis due to defects in mesoderm formation and axial organization (Ding et al., 1998; Liguori et al., 2003) . Notably, mouse cripto mutants exhibit defects in myocardial development as evidenced by the absence of expression of terminal myocardial differentiation genes such as aMHC and MLC2v (Ding et al., 1998; Xu et al., 1998) . Unfortunately, the early lethality observed in cripto À/À mice occurs before a stage in which the role of cripto in cardiogenesis can be evaluated. In vitro analysis of Cripto-deficient ES cells, by overcoming the complexity of the in vivo situation, led to novel insights into the functional role of cripto in cardiomiogenesis (Xu et al., 1998 (Xu et al., , 1999 Parisi et al., 2003) .
Activation of Cripto signaling cascade is an early event in the cardiogenic differentiation of mouse ES cells
The earliest event in heart formation is commitment of mesodermal cells to a cardiogenic 'fate' and their migration into anterolateral regions of the embryo during late gastrulation (Olson and Srivastava, 1996) . In amphibians and avians, heart development requires positive signals from adjacent endoderm, including extracellular factors such as bone morphogenetic proteins (BMPs), transforming growth factor (TGF)-b and fibroblast growth factors (FGFs). On the other hand, Wnt-mediated signals from the underlying neural tube and notochord suppress cardiomyocyte specification (Olson and Srivastava, 1996) . In mammals, ES cells have been largely used to study the early event of cardiac development (Maltsev et al., 1993; Boheler et al., 2002; Dell'Era et al., 2003) . Indeed, ES cells normally differentiate as aggregates, termed as embryoid bodies (EBs), which differentiate into a wide variety of specialized cell types, including cardiomyocytes. Within the developing EBs, cardiomyocytes are located between the epithelial layer and a basal layer of mesenchymal cells (Hescheler et al., 1997) and are readily identifiable because, within 7 days after removal of leukemia inhibitor factor (LIF), they spontaneously contract. During differentiation, cardiac-specific genes are expressed in a developmental continuum, which closely recapitulates the developmental pattern of cardiogenesis (Boheler et al., 2002) . One outstanding question is what are the signaling networks that drive ES cells to a cardiac destiny? The biochemical stimuli regulating this process are still largely unknown.
By using EBs derived from Cripto À/À ES cells, it has been shown that cripto is essential for cardiogenesis in culture (Xu et al., 1998) ; indeed, Cripto À/À EBs do not produce contracting cardiomyocytes even during extended culture periods (Xu et al., 1998) . These cells thus represent a good source to explore the molecular mechanisms underlying this process, and have been successfully used to elucidate the dynamic of Cripto signaling required for differentiation of cardiac precursors from ES cells. Indeed, kinetic experiments performed by adding recombinant Cripto protein directly to the culture medium of Cripto À/À ES cells indicate that Cripto is required in a precise moment during differentiation, after which it fails to specify the cardiac lineage. Actually, addition of Cripto protein during the 0-2 day interval effectively restored the differentiation ability of Cripto À/À ES cells; however, addition at later time points results in dramatically reduced cardiomyocyte differentiation (Figure 1) (Parisi et al., 2003) . These functional data are supported by expression data showing that endogenous Cripto protein is present at the earliest stages of ES cell differentiation and that it is absent at stages where contracting EBs start to appear (Parisi et al., 2003) .
Based on these considerations, it turns out that Cripto signaling is required for cardiac commitment of stem cells rather than for terminal differentiation of cardiomyocytes in culture.
Molecular basis of Cripto signaling in ES cell differentiation and cardiomiogenesis
Although a general outline of Cripto signaling pathway and its role during development has emerged, our current understanding is still scarce. Molecular genetic experiments in mice, Xenopus and Zebrafish point to a strong functional link between EGF-CFC protein and the TGF-b molecule, Nodal (Gritsman et al., 1999; Minchiotti et al., 2001; Reissmann et al., 2001; Yeo and Whitman, 2001 ). For instance, mouse cripto mutant embryos share some phenotypic similarities to Nodal mutants; however, cripto mutants are not severely affected as Nodal mutants, thus suggesting that Cripto does not mediate all Nodal signaling (Ding et al., 1998) . It is worth noting that Cripto cannot trigger the Nodal pathway itself, thus indicating that it acts as an essential cofactor for the Nodal pathway (Cheng et al., 2003) .
Both receptor reconstitution experiments and coimmunoprecipitation assays have helped to unravel the biochemical interactions of Cripto, Nodal and the Activin type I serine/threonine kinase receptors (Alk4 or Alk7). Receptor reconstitution experiments in Xenopus embryos have shown that Cripto interacts with ALK4 to permit Nodal binding to the ALK4/Activin type II serine/threonine kinase receptor (Act-RII) complex, leading to Smad phosphorylation ). In addition, Cripto was shown to be implicated in Nodal signaling via the orphan receptor ALK7, since its expression enhances the ability of ALK7 and ActRIIB to respond to Nodal ligands (Reissmann et al., 2001) . Finally, in co-immunoprecipitation assays, a purified recombinant Cripto protein has been shown to directly bind Nodal as well as the ALK4 and ALK7 receptors in the absence of any coreceptor, thus suggesting a cooperation mechanism between these two receptors and Cripto in mediating Nodal signaling (Reissmann et al., 2001) .
Based on these observations, membrane-bound Cripto appears to recruit Nodal to an Activin type I receptor (Alk4 or Alk7) and to Activin type II receptors (ActRII); upon receptor activation, intracellular effectors Smad2 and/or Smad3 are phosphorylated and accumulate together with Smad4 in the nucleus to activate downstream target genes (Reissmann et al., 2001; Yeo and Whitman, 2001 ). More recently, it has been shown that Cripto can also block activin signaling in cell culture assays and it associates in vitro with activin and ActRII (or ActRIIB) to block the assembly of an Alk4 complex Gray et al., 2003; Harrison et al., 2005) . It is thus suggested that Cripto could promote tumorigenesis both by inhibiting the tumor suppressor activity of the Activin and by mediating signaling by Nodal or related TGF-b ligands (Shen, 2003) .
Besides its role in mediating Nodal and/or Activin signaling, Cripto has been shown to activate nonTGF-b signaling pathways. Indeed, activation of the ras/raf/ mitogen-activated protein kinase (MAPK) and PI3K/ AKT pathways by Cripto has been demonstrated in both mouse and human mammary epithelial and Cripto and stem cells G Minchiotti cervical carcinoma cells; however, the relationships between these pathways and the Nodal pathway is still unclear (Bianco et al., 2002 . It is thus convincing that, although involved in Nodal signaling, Cripto protein may modulate different signaling pathways to mediate its different functional roles. As a first attempt to unravel the signaling pathways activated by Cripto in cardiomiogenesis, the controlled differentiation of Cripto À/À ES cells has provided a powerful system. Indeed, stimulation of Cripto À/À ES with recombinant Cripto has been shown to activate Smad2 (Parisi et al., 2003) . Interestingly, acute stimulation by Cripto, while competent in activating Smad2, is insufficient to achieve proper terminal cardiac differentiation, thus indicating that not only the particular timing but also the duration of Cripto signaling contributes to cardiomyocyte specification (Figure 2) .
Data on P19CL6 cells indicate that the Smad pathway is indispensable for normal cardiomyocyte differentiation (Monzen et al., 2001 ) thus suggesting that temporal and spatial regulation of the Smad pathway may be important for normal cardiac development from initial cardiomyocyte differentiation to terminal cardiac morphogenesis (Monzen et al., 2001) . Intracellular activation of Smad2, upon stimulation with recombinant Cripto, require assembly of an active activin type I and type II receptor complex. According to a functional role of Alk4 receptor in Cripto-dependent cardiogenesis, overexpression of an activated form of Alk4 restores the ability of Cripto À/À ES cells to differentiate into cardiomyocytes.
Besides TGF-b ligand Nodal, Cripto has been shown to interact with another member of the TGF-b superfamily, namely Vg1/GDF1; both ligands use the same type I receptor (Alk4) and the type II receptors ActRIIA/IIB and requires Cripto as an essential coreceptor in their signaling transduction (Cheng et al., 2003) . Loss-of-function experiments performed using Nodal antagonists, either Cerberus or Cerberus-S, indicate that Nodal signaling is indeed required to support Cripto-regulated cardiac induction and differentiation in ES cells. Addition of Nodal-antagonist Cerberus Short, which specifically blocks Nodal by direct binding to the ligand (Piccolo et al., 1999) , results in a strong inhibition of Cripto activity in promoting cardiogenesis (Parisi et al., 2003) and provides direct evidence for a functional role of Alk4/Nodal pathway in Cripto-mediated specification of the cardiac lineage (Figure 3) .
The dynamics of Cripto signaling described so far, (i) the timing of initiation, (ii) the strength of the signal and (iii) the signaling duration, are all critical parameters for correct specification and differentiation of the cardiac lineage (Figures 1 and 2 ). In the early embryo, cells experience factor concentrations that change with time and thus must select the correct concentration in order to obtain their major response (Gurdon et al., 1998; Gurdon and Bourillot, 2001 ); we suggest that Cripto has a key role in the molecular mechanism underlying this process in ES cells.
Several reports have described the fact that Cripto is modified by the addition of sugar residues, including a rare case of fucosylation (Schiffer et al., 2001) . These modifications are essential for Cripto function, suggesting that, as in a rising population of key developmental regulators, the activity of Cripto could be controlled by the extent of glycosylation/fucosylation (Rosa, 2002) . Interestingly, an alanine substitution in the site of Ofucosylation ) generates a Cripto mutant protein that is still competent to promote Cripto and stem cells G Minchiotti cardiomyocyte differentiation, thus suggesting that fucosylation of Cripto is not strictly required for facilitating Nodal signaling in ES cells (Parisi et al., 2003) . Accordingly, mutant embryos lacking O-fucosyltransferase do not resemble cripto knockout phenotype thus suggesting a less stringent requirement for O-fucose on Cripto activity in vivo than in reporter assays (Shi and Stanley, 2003) .
Different timing of Cripto signaling induces different cell fates
Knockout mice for the cripto gene consist mostly of anterior neuroectoderm and lack posterior structures (Ding et al., 1998; Liguori et al., 2003) ; however, the critical timing of Cripto signaling required to achieve neural specification in mammalian embryos is not known. Intriguingly, disruption of cripto leads to spontaneous neuronal differentiation of ES cells in the presence of serum and in the absence of either specific inducers or defined culture conditions (Parisi et al., 2003) . Interestingly, kinetic experiments indicate that the timing of Cripto signaling required for priming ES cells to cardiomyocytes resembles the competence window of ES cells to acquire a neural fate (Parisi et al., 2003) . Indeed, addition of effective doses of Cripto protein to Cripto À/À ES cells during the 0-2 day interval restores cardiomyocyte differentiation (Figure 1 ) and, at the same time, results in a dramatic inhibition of neural differentiation (Figure 4) . Conversely, addition of recombinant Cripto at later time points (i.e. 3-6 day interval) results in progressive impairment of cardiac differentiation, as well as in increased competence of Cripto À/À ES cells to acquire a neural phenotype (Parisi et al., 2003) thus suggesting that different timing of Nodal-dependant Cripto signaling induces different fates in ES cells (Figure 4) .
How neural stem cells are formed initially during mammalian development is yet to be clarified and the mechanism of neuroectoderm formation from ES cells is still debated (Munoz-Sanjuan and Brivanlou, 2002) . Several different approaches have been used to investigate the mechanisms underlying the generation of neural tissue from ES cells. The first attempt showed that dilution of mouse ES cells in vitro facilitates neural differentiation compared with ES cells cultures at high density (Tropepe et al., 2001) . Interestingly, this effect can be mimicked by BMP inhibitors such as noggin and Cerberus, as well as by using ES cells with a targeted mutation of Smad4 gene, a critical intracellular transducer of TGF-b signaling pathway (Tropepe et al., 2001) . Furthermore, evidence has been provided that Wnt signaling, BMPs as well as extracellular matrix components induce nonneural differentiation of ES cells (Aubert et al., 2002; Ying et al., 2003) . More recently, it has been shown that the generation of neural precursors from ES cells in serum-free conditions occurs largely without concomitant induction of mesodermal and Cripto and stem cells G Minchiotti endodermal tissues (Watanabe et al., 2005) ; in this condition, blockade of either Nodal or Wnt signaling, upon treatment of ES cells with the antagonist molecules Dkk1 and LeftyA, respectively, results in further enhancement of neural differentiation (Watanabe et al., 2005) . Finally, data have been provided which indicates that in human ES cells over-expression of Nodal antagonists (i.e. Lefty and Cerberus-short) leads to extensive neuroectoderm development, whereas Nodal gain-offunction experiments result in inhibition of neuroectoderm development (Vallier et al., 2004) .
Based on the above considerations, several data would support the hypothesis that the establishment of neural identity from uncommitted mammalian ES cells occurs by 'default', and that suppression of neural determination by induction of alternative fates is a principle conserved between ES cells and the embryo (Munoz-Sanjuan and Brivanlou, 2002) . However, this issue is still debated; in fact, besides exogenous inhibitory factors (either soluble or paracrine), recent data suggest that cell adhesion may also have a key role in neural differentiation of ES cells (Watanabe et al., 2005) . Interestingly, it has been recently described that Cripto À/À ES cells show enhanced neurogenesis compared to wild-type ES cells (Sonntag et al., 2005) following the five stage-neuronal differentiation protocol, a method described for efficient generation of dopaminergic and serotonergic neurons from ES cells (Lee et al., 2000; Chung et al., 2002) . However, multilineage cell types have also been found in Cripto À/À ES cells, thus suggesting that loss of function of Cripto is not sufficient to result in a 'default' neural pathway, at least in this in vitro paradigm (Sonntag et al., 2005) .
Generation of specific neural subtypes from Cripto

À/À
ES cells
Besides improving our understanding of neuroectoderm formation in mammals, the recent breakthroughs in stem cell research have opened up new possibilities for cell replacement therapy in neurodegenerative diseases, such as Parkinson's disease (PD) (Arenas, 2002; Rossi and Cattaneo, 2002; Isacson et al., 2003; Lindvall et al., 2004) . Neurons with dopaminergic phenotype surviving transplantation have been generated in culture from ES cells . Naive ES cells, when grafted at low concentration, develop into normal midbrain-like DA neurons that cause gradual and sustained behavioral restoration of DA-mediated motor asymmetry. However, these grafting experiments show that ES cells also develop into unwanted cell types, resulting in tumor formation . Effective strategies must thus be developed to identify both the molecules and mechanisms that are required to obtain populations of ES cells enriched in neural cells and eventually demonstrate that these cells properly integrate in the injured brain (Lindvall et al., 2004) . Over the last few years, several reports have described methods for generating neural cells from ES cells in vitro (Bain et al., 1995; Kawasaki et al., 2000; Lee et al., 2000; Ying et al., 2003; Watanabe et al., 2005) . For example, when retinoic acid (RA) is added to EBs in culture, a high proportion of neural cells are generated (Bain et al., 1995) . However, the action of retinoic acid is pleiotropic and of indeterminate physiological relevance; it is therefore preferable to avoid RA treatment. Furthermore, RA evokes caudalization of induced neural tissue and inhibits the production of rostral CNS tissue (Mizuseki et al., 2003) .
Alternatively, a good proportion of neural differentiation is achieved by coculture of ES cells with a particular stromal cell line, PA6 (Kawasaki et al., 2000) . The effect of PA6 cells is attributed to an undefined neural inducing activity; the factor(s) responsible has been termed stromal cell-derived inducing activity (SDIA) and the nature of the factors that mediate neurogenesis is still unknown. When cultured with PA6 cells under serum-free condition, a high percentage of midbrain dopaminergic neurons are generated (Kawasaki et al., 2000) .
In this scenario, suppression of Cripto could represent a powerful strategy to improve neuronal differentiation and generate specific neuronal subtypes from ES cells. Accordingly, we have recently shown that in the absence of cripto, cells more frequently differentiate into tyrosine hydroxylase (TH)-immunoreactive cells. Furthermore, treatment of Cripto À/À -derived EBs with Shh and/or FGF8, two factors important for ventral midbrain dopaminergic (DA) neurons, strongly increases the proportion of TH-positive cells as well as the expression of dopaminergic transporter (DAT), compared to wildtype ES cells (Parish et al., 2005) . Finally, both Wnt1 and Ret, required for survival and differentiation of DA neurons (Castelo-Branco et al., 2003) , are over-expressed in Cripto À/À compared to wild-type EBs. Suppression of cripto thus allows cells to spontaneously differentiate to a neural fate, and can increase the cellular pool for dopaminergic differentiation (Parish et al., 2005) . The increased neural induction in Cripto À/À ES as well as the absence of at least some aspects of terminal mesoderm differentiation have led to hypothesize that suppression of Cripto may reduce unwanted cell development, thus improving the therapeutic use of ES cells. Interestingly, Cripto À/À ES cells, when grafted at low density, generate TH-positive cells able to restore behavior in an animal model of PD and, furthermore, do not lead to the formation of teratomas (Parish et al., 2005) . It is worth noting that transplantation of higher doses of Cripto À/À ES cells results in generation of terminally differentiated mesodermal cell types (Sonntag et al., 2005) , suggesting that loss of Cripto activity could be compensated in transplant condition by spatial constraint and by the host mouse adult striatum (Sonntag et al., 2005) . This apparent discrepancy could be explained by the different doses of ES cells transplanted into the animals.
Cripto is thus a key regulator of ES cell fate; indeed, it is strictly required in an early acting window to negatively regulate neural differentiation and, at the same time, to permit differentiation of ES cells to cardiac fate. Cripto may represent an attractive target for future therapeutic approach; however, a better understanding of the events that follow Cripto inhibition and mediate acquisition of neural fate are needed as a crucial step in the ongoing efforts to employ ES cells in regenerative medicine.
Perspectives
The identification of signaling molecules that regulate ES cell self-renewal, as well as differentiation to specific cellular subtypes will be very useful for improving our understanding of these processes in both adult stem cells and progenitor cells. A combination of genetic, biochemical and cell biology approaches will be successful to (i) increase our knowledge of the molecular mechanisms regulating early events of mammalian development, (ii) identify and isolate progenitor cells, (iii) design novel strategies for directing differentiation of ES cells to specific subtypes and (iv) eventually strengthen clinical application of stem cells. In this respect, the cripto gene is a hallmark of mouse and human ES cells and may thus represent a preferential target for future cell-based therapeutic approaches.
